263 related articles for article (PubMed ID: 21955936)
1. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
6. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
[TBL] [Abstract][Full Text] [Related]
7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
16. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
